ACT is leading innovation within the cancer biotechnology sector through its development and delivery of 'first in class' drugs.  Historically, a barrier to using peptides therapeutically came from finding a way for the peptide to physically enter a cell. To overcome this barrier, we have fused our peptides with a cell penetration domain which allows the peptide to  enter the cell and effect intracellular processes.


Arizona Cancer Therapeutics is managed by Alliance Therapeutics